Quantum Genomics, a biopharmaceutical research company developing new treatments in the field of cardiovascular diseases, has announced that it concluded a collabration agreement with a major company in the field of animal health, for the QGC101 programme. This agreement aims to continue the development of a drug candidate for the treatment of heart failure in dogs.
[button link=”http://www.quantum-genomics.com/www/wp-content/uploads/2015/06/QUANTUM_ACCORD_SANTE_ANIMALE_13022014_VF.pdf” target=”_blank” title=”Download the PDF – French only” size=”small” color=”red”]
